It is unknown why vericiguat does not have a more dramatic therapeutic impact in individuals with HFrEF and concurrent CAD, given the expected involvement of reduced sGC activity in endothelial dysfunction and microvascular illness. The gene discussed is SGCB; the disease is endothelial dysfunction.